News

Akari Therapeutics Plc has announced a strategic partnership with WuXi XDC to accelerate the development of its next-generation antibody-drug conjugate (ADC) technology, marking a…
Read More...

Eli Lilly and Company has announced a definitive agreement to acquire Centessa Pharmaceuticals in a transaction valued at approximately $6.3 billion upfront, with additional…
Read More...

Teva Pharmaceutical Industries has announced a series of significant milestones in its biosimilars portfolio, underscoring progress in its broader “Pivot to Growth” strategy and…
Read More...

Symeres has entered into a strategic collaboration with Ambagon Therapeutics to explore a promising new class of small molecules known as molecular glues for the treatment of colorectal…
Read More...

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, marking a significant step in Biogen’s strategy to…
Read More...

Biogen Inc. has announced that the U.S. Food and Drug Administration has approved a high-dose regimen of its therapy SPINRAZA for the treatment of spinal muscular atrophy (SMA), marking…
Read More...

Otsuka Pharmaceutical has announced plans to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, strengthening its presence in the neuropsychiatric treatment space…
Read More...

Corcept Therapeutics has announced that the U.S. Food and Drug Administration has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with…
Read More...

Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate the clinical development of antibody-drug conjugates (ADCs) in oncology, highlighting the growing…
Read More...

Cognito Therapeutics has partnered with Ochsner Health to establish a new Brain Health Collaboratory aimed at advancing innovative approaches to treating cognitive decline and…
Read More...

Merck & Co.—known as MSD outside North America—has announced a definitive agreement to acquire Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening…
Read More...

UCB has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending an update to the marketing authorization for…
Read More...

Japan’s Ministry of Health, Labour and Welfare has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous…
Read More...

Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines, a privately held firm focused on developing T cell engager therapies for autoimmune diseases. The move…
Read More...

Quotient Therapeutics has entered a multi-year research collaboration with Merck & Co.—known as MSD outside the United States and Canada—to identify new drug targets for…
Read More...

Viz.ai has announced a strategic partnership with Alnylam Pharmaceuticals aimed at improving the early detection and diagnosis of cardiac amyloidosis, a serious and often underdiagnosed…
Read More...

UCB has announced plans to establish a major new biologics manufacturing facility in Gwinnett County, Georgia, marking a significant step in the company’s long-term U.S. expansion…
Read More...

Zealand Pharma has announced plans to establish a new research hub in Cambridge, Massachusetts, marking a significant expansion of its global footprint and reinforcing its ambitions in…
Read More...

Kali Therapeutics has entered into a licensing agreement with Sanofi for the development of a novel tri-specific T-cell engager, KT501, aimed at treating a broad range of B…
Read More...

LGM Pharma has announced a $9 million expansion across its U.S. manufacturing network, marking the second phase of a broader contract development and manufacturing organization (CDMO)…
Read More...